Navigation Links
Pharmasset Reports Fiscal Year End 2009 Financial Results
Date:11/25/2009

e voluntarily terminated our phase 3 studies of clevudine after we became aware of a number of spontaneous Serious Adverse Event reports and Events of Special Interest in patients receiving clevudine as prescribed therapy for HBV in South Korea, where the drug is marketed by Bukwang under the trade name Levovir, and in Hong Kong, where clinical studies were being conducted under the sponsorship of Bukwang. Given the number and severity of cases observed in South Korea and Hong Kong, we determined it was in the best interest of patients to voluntarily terminate our registration studies. All patients have now completed the follow-up period and we anticipate concluding activities by the end of the quarter ending December 31, 2009.

"Pharmasset has had a tremendous year on all fronts," said Schaefer Price, Pharmasset's President and CEO. "In collaboration with Roche, we are advancing our first in class nucleoside analog, RG7128, through a phase 2b trial and also exploring the paradigm-changing model of an all oral (interferon sparing) regimen for HCV. We reported best in class results with our second generation nucleotide analog inhibitor, PSI-7851 and anticipate starting phase 2a trials in the first quarter 2010. We believe nucleosides/tides will have an advantage in the marketplace when used with the current standard of care, due to their high RVR rates, pan-genotype activity and high barrier to resistance. In the future, as we move towards oral combinations, we believe our nucleoside/tides have the potential to be used in combination with one another and with other classes of direct acting antivirals."

Financial Results

For the fiscal year ended September 30, 2009 Pharmasset reported revenues of $13.3 million, compared with revenues of $1.9 million for the fiscal year 2008. The receipt of a $10.0 million milestone from Roche for the initiation of the phase 2b study with RG7128 led to higher reported revenues in the fiscal year
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
3. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
4. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
5. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
6. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
7. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
8. Pharmasset Reports Fiscal Year End 2008 Financial Results
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... York , August 4, 2015 ... titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, ... Others) - Global Industry Analysis, Size, Volume, Share, Growth, ... According to a new market report published by Transparency ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ...
(Date:8/4/2015)... Aug. 4, 2015 BioElectronics Corporation (OTC ... Musculoskeletal Pain Therapy medical devices, announced today that ... ActiPatch 7-day trial device has been published in ... Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 ... submitted an assessment.  Chronic pain ...
(Date:8/4/2015)... DUBLIN , Aug. 4, 2015 Research ... of the "Alcohol Ethoxylate Market by Application (Household ... Geographies Global Market Trends, Forecasts to 2019" report ... of alcohol ethoxylate was valued at $5,124.9 million in ... of about 3.5% from 2014 to 2019. The data ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3
... SALT LAKE CITY, May 11, 2011 Dynatronics Corporation (Nasdaq: ... its quarter ended March 31, 2011 during the morning of ... a conference call for investors later that day at 1:00 ... interested in participating should call (800) 926-7510 and use access ...
... 11, 2011 BioSpecifics Technologies Corp. (NASDAQ: ... collagenase-based products, today announced that BioSpecifics, President, Tom Wegman, ... Annual Equity Conference on Tuesday, May 17th at 9:30am ... A live webcast of the presentation can ...
Cached Medicine Technology:
(Date:8/4/2015)... ... ... Sponsored by Gila River Casinos, the charity event helps raise funds and ... to the New Foundation AZ spokesperson , the organization is still looking for ... foursome for the tournament, as well as getting their company advertised on a banner ...
(Date:8/4/2015)... Birmingham, OH (PRWEB) , ... August 04, 2015 ... ... announce that it has joined the American Association of Tissue Banks (AATB) as ... AATB and its mission “to honor donors, and to save and improve lives ...
(Date:8/4/2015)... ... 2015 , ... Atlantic Health System, one of the largest health care organizations ... top five in their list of the 20 Best Workplaces in Health Care. , ... Centers, Goryeb Children’s Hospital and Atlantic Rehabilitation, is the highest-ranking company from New Jersey ...
(Date:8/4/2015)... ... August 04, 2015 , ... Rhode Island Medical Imaging (RIMI) is pleased ... Medical Building on Wake Robin Road in Lincoln, RI. This satellite office will ... the most extensive out-patient x-ray hours in the state, which includes evenings and weekends. ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... Healthy Origins® Cognizin® is a trademark for Citicoline, a nutrient that supports memory ... for those applications which have more of a semi-solid composition. Vegetarian capsules ...
Breaking Medicine News(10 mins):Health News:The New Foundation AZ to Host Charity Golf Tournament 2Health News:The New Foundation AZ to Host Charity Golf Tournament 3Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 2Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 3Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 4Health News:Rhode Island Medical Imaging Opens Satellite Imaging Center on Wake Robin Road in Lincoln 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3
... News) -- Heart attack patients who are exposed to low-dose ... increased risk of cancer, a new study finds. Canadian ... attack between April 1996 and March 2006 and had no ... 77 percent of the patients underwent at least one cardiac ...
... MONDAY, Feb. 7 (HealthDay News) -- Living in a ... such as smoking or obesity, researchers have found. ... University researchers asked 17-year-olds and their mothers to provide ... how connected their community is and the degree of ...
... 4 (HealthDay News) -- New research shows that obesity is ... but people in the wealthiest nations are managing to reduce ... courtesy of three studies published online Feb. 3 in ... in Western countries fend off some of the physical effects ...
... --- Small calf muscles may be a feminine trait, but ... disadvantage. Researchers at Northwestern Medicine point to the smaller calf ... women with PAD to experience problems walking and climbing stairs ... The study was published in the February 2011 issue of ...
... Behen HealthDay Reporter , FRIDAY, Feb. 4 (HealthDay ... feel guilty about, a new study suggests that the more ... Researchers at American University, Cornell University and the University of ... the cumulative time that a child,s mother worked was associated ...
... News) -- Children who know two languages find it easier ... one language, a new study finds. The research included ... English. One group included 40 students from the former Soviet ... Hebrew as a second language. The other group included 42 ...
Cached Medicine News:Health News:Heart Scans May Raise Cancer Risk, Study Finds 2Health News:Community Has a Role in Health of Low-Income Kids 2Health News:Obesity Has Nearly Doubled Worldwide Since 1980: Report 2Health News:Peripheral artery disease harder on women 2Health News:The More Mom Works, the Heavier Her Kids Get: Study 2Health News:The More Mom Works, the Heavier Her Kids Get: Study 3Health News: Bilingual People More Adept at Learning Third Language 2
Curved with catch....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Rhoton #12 straight point needle semisharp, titanium....
Medicine Products: